Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer.
Despite the benefit of adjuvant hormonal therapy (HT) on mortality among women with breast cancer (BC), many women are non-adherent with its use. We investigated the effects of early discontinuation and non-adherence to HT on mortality in women enrolled in Kaiser Permanente of Northern California (KPNC). We identified women diagnosed with hormone-sensitive stage I-III BC, 1996-2007, and used automated pharmacy records to identify prescriptions and dates of refill. We categorized patients as having discontinued HT early if 180 days elapsed from the prior prescription. For those who continued, we categorized patients as adherent if the medication possession ratio was ≥80%. We used Cox proportional hazards models to estimate the association between discontinuation and non-adherence with all-cause mortality. Among 8,769 women who filled at least one prescription for HT, 2,761 (31%) discontinued therapy. Of those who continued HT, 1,684 (28%) were non-adherent. During a median follow-up of 4.4 years, 813 women died. Estimated survival at 10 years was 80.7% for women who continued HT versus 73.6% for those who discontinued (P < 0.001). Of those who continued, survival at 10 years was 81.7 and 77.8% in women who adhered and non-adhered, respectively (P < 0.001). Adjusting for clinical and demographic variables, both early discontinuation (HR 1.26, 95% CI 1.09-1.46) and non-adherence (HR 1.49, 95% CI 1.23-1.81), among those who continued, were independent predictors of mortality. Both early discontinuation and non-adherence to HT were common and associated with increased mortality. Interventions to improve continuation of and adherence to HT may be critical to improve BC survival.
Hershman
Dawn L
DL
Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University Medical Center, 161 Fort Washington Avenue, 10-1068, New York, NY 10032, USA. dlh23@columbia.edu
Shao
Theresa
T
Kushi
Lawrence H
LH
Buono
Donna
D
Tsai
Wei Yann
WY
Fehrenbacher
Louis
L
Kwan
Marilyn
M
Gomez
Scarlett Lin
SL
Neugut
Alfred I
AI
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008875:Middle Aged; D010349:Patient Compliance; D016016:Proportional Hazards Models; D013629:Tamoxifen / Q000627:therapeutic use*; D047368:Tumor Burden
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D013629:Tamoxifen
J Clin Oncol. 2003 Feb 15;21(4):602-6
12586795
Br J Cancer. 2008 Dec 2;99(11):1763-8
18985046
Breast Cancer Res Treat. 2003 Sep;81(1):21-31
14531494
Lancet. 2005 May 14-20;365(9472):1687-717
15894097
J Natl Cancer Inst Monogr. 2001;(30):56-61
11773293
Breast Cancer Res Treat. 2006 Sep;99(2):215-20
16541307
J Clin Oncol. 2005 Jan 20;23(3):619-29
15545664
Blood. 2009 May 28;113(22):5401-11
19349618
Lancet. 1992 Jan 11;339(8785):71-85
1345869
J Am Coll Surg. 2008 Jan;206(1):66-75
18155570
Cancer. 2007 Aug 1;110(3):660-9
17582625
J Natl Cancer Inst. 1998 Aug 19;90(16):1205-11
9719081
J Natl Cancer Inst. 2002 May 1;94(9):652-61
11983753
J Clin Oncol. 2009 Jul 20;27(21):3445-51
19451445
Med Care. 2002 Aug;40(8 Suppl):IV-26-35
12187165
Ann Oncol. 2010 Feb;21(2):283-290
19628570
Med Care. 2002 Aug;40(8 Suppl):IV-75-81
12187172
Curr Med Res Opin. 2009 Sep;25(9):2303-10
19635045
N Engl J Med. 1994 May 5;330(18):1253-9
8080512
Oncology. 2006;71(1-2):1-9
17344666
J Natl Cancer Inst. 1996 Nov 6;88(21):1543-9
8901852
Cancer Invest. 1999;17(7):545-6
10518199
N Engl J Med. 1995 Apr 6;332(14):901-6
7877646
J Clin Oncol. 2010 Sep 20;28(27):4120-8
20585090
Pharmacoeconomics. 2007;25(6):481-96
17523753
N Engl J Med. 2003 Nov 6;349(19):1793-802
14551341
N Engl J Med. 2004 Mar 11;350(11):1081-92
15014181
Med Care. 2006 May;44(5):471-7
16641666
J Chronic Dis. 1987;40(5):373-83
3558716
J Clin Oncol. 2006 May 20;24(15):2368-75
16618946
Cancer. 2007 Mar 1;109(5):966-74
17243096
J Clin Oncol. 2005 Sep 20;23(27):6639-46
16170171
Lancet. 2005 Jan 1-7;365(9453):60-2
15639680
Cancer. 2007 Mar 1;109(5):832-9
17243168
Br J Cancer. 2008 Apr 8;98(7):1197-203
18349836
Ann Oncol. 2009 Mar;20(3):431-6
19150950
Cancer Causes Control. 2001 Oct;12(8):703-11
11562110
J Clin Oncol. 2008 Feb 1;26(4):556-62
18180462
N Engl J Med. 2005 Aug 4;353(5):487-97
16079372